Physician profile
Andrew S Fischer
NPI 1528453057
$11,375.26
in general payments reported to CMS, 2019-2025
31 companies · $2,729 in 2025
The $2,729 reported for 2025 was more than what 91% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $331 · 2021: $1,376 · 2022: $1,743 · 2023: $2,269 · 2024: $2,927 · 2025: $2,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,715 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,714.83 |
| Education | $209.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,397.39 | 2020-2025 | |
| Janssen Biotech, INC. | $1,208.00 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,074.98 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $949.88 | 2022-2025 | |
| Lilly USA, LLC | $877.89 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Revance Therapeutics, INC. | $839.29 | 2024-2025 | Daxxify, Daxi |
| Sun Pharmaceutical Industries INC. | $631.86 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $526.82 | 2020-2025 | Nemluvio, Oracea, Aklief |
| Genzyme Corporation | $523.55 | 2021-2025 | |
| Incyte Corporation | $426.20 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $405.31 | 2023-2024 | Vtama |
| Pfizer INC. | $398.67 | 2021-2025 | |
| Leo Pharma INC. | $356.89 | 2020-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $334.13 | 2023-2025 | Zoryve |
| Amgen INC. | $257.71 | 2020-2025 | Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $182.04 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.42 | 2021-2025 | Arazlo, Jublia, Duobrii |
| Mayne Pharma Commercial LLC | $153.23 | 2023-2024 | |
| Vyne Pharmaceuticals INC. | $149.95 | 2021 | |
| Ucb, INC. | $131.78 | 2022-2025 | Cimzia, Bimzelx |
| Almirall LLC | $127.36 | 2021-2023 | Klisyri |
| Verrica Pharmaceuticals INC. | $40.47 | 2024 | Ycanth |
| Journey Medical Corporation | $37.22 | 2022-2023 | |
| Hill Dermaceuticals, INC. | $35.89 | 2020 | |
| Organon LLC | $33.32 | 2025 | Vtama |
| Alnylam Pharmaceuticals INC. | $22.59 | 2025 | Givlaari |
| Epi Health, LLC | $21.10 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $19.24 | 2021 | |
| Botanix Sb INC | $17.92 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $15.55 | 2021 | |
| Strata Skin Sciences, INC. | $13.61 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.